EichorEICHOR
Condition: Leukemia Lymphoid Synced from ClinicalTrials.gov · August 09, 2026

Recruiting studies: Leukemia Lymphoid

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Phase 1 · 1 location(s) · Liping Dou · NCT07677878Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL
Phase N/A · 4 location(s) · IRCCS Burlo Garofolo · NCT05811845A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cel
Phase 2/Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06860269PTCy and ATG for MSD and MUD Transplants
Phase 1/Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06299462NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07280494Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT07634653Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · 124 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05327894A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · 201 location(s) · Merck Sharp & Dohme LLC · NCT06136559A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Wi
Phase 3 · 30 location(s) · AstraZeneca · NCT07509151CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04016129Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Phase 1 · 16 location(s) · New York Medical College · NCT04972942Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Rec
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06967610CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917Venetoclax Combined With Azactidine in the Treatment of ALAL
Phase 2 · 1 location(s) · Sheng-Li Xue, MD · NCT05901974Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leuke
Phase 1/Phase 2 · 2 location(s) · University of Chicago · NCT06207123Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · 182 location(s) · Alliance for Clinical Trials in Oncology · NCT07321652Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06507514Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia
NA · 4 location(s) · Rigshospitalet, Denmark · NCT04209244
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.